It’s times like this that make us nostalgic for a multi-firm blog.

Yesterday, the Pennsylvania Superior Court issued a decision affirming the decertification of a putative non-personal-injury class of consumers who purchased Neurontin for alleged “off-label” uses. We can’t comment on the case because of Dechert’s involvement, but you can take a look at the unanimous decision in Clark v. Pfizer here.